Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
Ventyx Biosciences, Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/11/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/11/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/10/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 10/10/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 10/06/2023 |
4
| Mohan Raju (CEO) has filed a Form 4 on Ventyx Biosciences, Inc.|
Txns:
| Sold 30,000 shares
@ $29.1077, valued at
$873.2k
Exercised 30,000 options to buy
@ $8.04, valued at
$241.2k
|
|
| 10/05/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 10/04/2023 |
4
| Krueger Christopher W (Chief Business Officer) has filed a Form 4 on Ventyx Biosciences, Inc.|
Txns:
| Sold 14,006 shares
@ $29.9291, valued at
$419.2k
Sold 994 shares
@ $30.6959, valued at
$30.5k
Exercised 15,000 options to buy
@ $8.04, valued at
$120.6k
|
|
| 10/04/2023 |
4
| Nuss John (Chief Scientific Officer) has filed a Form 4 on Ventyx Biosciences, Inc.|
Txns:
| Sold 9,277 shares
@ $29.937, valued at
$277.7k
Sold 723 shares
@ $30.7155, valued at
$22.2k
Exercised 1,401 options to buy
@ $0.2, valued at
$280.2
Exercised 7,972 options to buy
@ $3.54, valued at
$28.2k
Exercised 627 options to buy
@ $8.04, valued at
$5k
|
|
| 10/03/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 10/03/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
8-K
| Quarterly results|
Docs:
|
"Ventyx Biosciences, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss Three months ended June 30, Six months ended June 30, 2023 2022 2023 2022 Operating expenses: Research and development $ 48,560 $ 14,676 $ 83,997 $ 32,085 General and administrative 8,585 5,722 15,700 11,060 Total operating expenses 57,145 20,398 99,697 43,145 Loss from operations Other expense: Interest income Other expense 5 6 79 Total other expense Net loss $ $ $ $ Unrealized gain on marketable securities 352 Foreign currency translation 38 61 Comprehensive loss $ $ $ $ Net loss per share, basic and diluted $ $ $ $ Weighted average common shares outstanding, basic and diluted 58,556,529 50,848,391 58,100,261 50,717,548 Ventyx Biosciences, Inc. Selected Condensed Consolidated Balance S..." |
|
| 08/08/2023 |
4
| Sandborn William J. (See Remarks) has filed a Form 4 on Ventyx Biosciences, Inc.|
Txns:
| Sold 2,086 shares
@ $32.6852, valued at
$68.2k
Sold 1,408 shares
@ $33.1167, valued at
$46.6k
|
|
| 08/08/2023 |
4
| Mohan Raju (CEO) has filed a Form 4 on Ventyx Biosciences, Inc.|
Txns:
| Sold 20,225 shares
@ $33.2017, valued at
$671.5k
Sold 8,898 shares
@ $34.0938, valued at
$303.4k
Sold 877 shares
@ $35.005, valued at
$30.7k
Exercised 30,000 options to buy
@ $8.04, valued at
$241.2k
|
|
| 08/08/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/07/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/04/2023 |
4
| Nuss John (Chief Scientific Officer) has filed a Form 4 on Ventyx Biosciences, Inc.|
Txns:
| Sold 8,887 shares
@ $35.5587, valued at
$316k
Sold 1,113 shares
@ $35.9171, valued at
$40k
Exercised 10,000 options to buy
@ $0.2, valued at
$2k
|
|
| 08/04/2023 |
4
| Krueger Christopher W (Chief Business Officer) has filed a Form 4 on Ventyx Biosciences, Inc.|
Txns:
| Sold 13,300 shares
@ $35.5452, valued at
$472.8k
Sold 1,700 shares
@ $35.9094, valued at
$61k
Exercised 15,000 options to buy
@ $8.04, valued at
$120.6k
|
|
| 08/04/2023 |
4/A
| Krueger Christopher W (Chief Business Officer) has filed a Form 4 on Ventyx Biosciences, Inc.|
Txns:
| Exercised 1,089 options to buy
@ $8.04, valued at
$8.8k
Exercised 13,911 options to buy
@ $0.2, valued at
$2.8k
|
|
| 08/03/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/03/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/01/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/01/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/01/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/31/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 07/26/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/25/2023 |
8-K
| Quarterly results |
| 07/25/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 07/19/2023 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
| 07/19/2023 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
| 07/19/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 07/13/2023 |
4
| NSV Partners III LP (10% Owner) has filed a Form 4 on Ventyx Biosciences, Inc.|
Txns:
| Sold 28,646 shares
@ $37.5414, valued at
$1.1M
Sold 3,275 shares
@ $37.6242, valued at
$123.2k
|
|
| 07/13/2023 |
4
| Subramaniam Somu (10% Owner) has filed a Form 4 on Ventyx Biosciences, Inc.|
Txns:
| Sold 28,646 shares
@ $37.5414, valued at
$1.1M
Sold 3,275 shares
@ $37.6242, valued at
$123.2k
|
|
| 07/11/2023 |
4
| Subramaniam Somu (10% Owner) has filed a Form 4 on Ventyx Biosciences, Inc.|
Txns:
| Sold 75,686 shares
@ $34.9879, valued at
$2.6M
Sold 20,718 shares
@ $35.8225, valued at
$742.2k
Sold 3,596 shares
@ $36.9277, valued at
$132.8k
Disposed of 1,030,341 shares
@ $0 |
|
|
|
|